A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Sponsor
Biotroy Therapeutics
Study ID
NCT07107204
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Leukemia
  • Lymphoma
  • Multiple Myeloma (MM)
  • Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • BT02 — DRUG
    BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Study Details

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Key Dates

First listed
Aug 6, 2025
Start date
Oct 31, 2025
Status verified
Jul 2025
Primary completion
Jan 31, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
116 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: dose escalation and expansion

Primary Outcome Measure

Adverse events [ Time Frame: Through the study completion, an average of 2.5 years ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies